The development of new cancer therapies is a resource-intensive endeavor. Licensing agreements enable academic institutions and biotechnology companies to pool their resources and expertise. These collaborations can accelerate the development process and enhance the likelihood of bringing innovative cancer treatments to patients. Moreover, licensing agreements provide a mechanism for sharing risks and rewards, which is particularly important given the high cost and uncertainty associated with drug development.
